Repertoire Immune Medicines Announces First Participant Dosed in Phase 1/2 Trial of RPTR-1-201, a T Cell-Targeted Immune Medicine for Advanced Solid Tumors PR Newswire Nawigacja wpisu MU will expand Springfield campus into 4‑year medical program – Springfield News-Leader National Infertility Week- Maternal Fetal Medicine – UConn Today
